ESC Congress 24 – Day 1 of the ESC Congress 2024 was filled with excitement as new clinical practice guidelines were unveiled, along with several highly anticipated Hot Line trials. 

Interventional experts Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (King Fahd Armed Forces Hospital, SA) are concluding the first day by providing practical summaries of the key guidelines and offering critical insights on selected trials relevant to clinical practice.

Day 1 Highlights:

0:25 – 03:20: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension
03:21 - 05:54: 2024 ESC Guidelines for the management of chronic coronary syndromes
05:58 - 09:28: 2024 ESC Guidelines for the management of atrial fibrillation
09:29 - 12:41: HELIOS-B: Primary Results from HELIOS-B, a Phase 3 Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
12:44 - 14:34: ABYSS: Beta-Blocker Interruption or Continuation after Myocardial Infarction
14:34 - 17:14: The STOP-or-NOT trial: Exploring the best strategy for the management of Renin-angiotensin system
inhibitors before surgery
 

Watch additional ESC 24 wrap-ups from Dr Alasnag and Dr Al-Shaibi, coming soon from Radcliffe Cardiology.

Recorded on-site at the ESC Congress 2024, London.

Editors: Mirjam Boros and Jordan Rance.
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles, David Ben-Harosh.
Support: This is an independent discussion produced by Radcliffe Cardiology.